An observational study in Tricuspid Regurgitation and Pulmonary Regurgitation, sponsored by Charite University, Berlin, Germany. Recruiting at 1 site in Germany. Open to participants aged 18 Years to 120 Years. Per ClinicalTrials.gov, last updated 2026-03-19.
Sponsored by Charite University, Berlin, Germany · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies in Tricuspid Valve Insufficiency with a site in Germany — 24 open to participants now, 31 under way, none of them phase 3. Tricuspid Valve Insufficiency · Germany.
Among the 51 studies in Tricuspid Valve Insufficiency with a site in Germany, this one is the 18th largest by planned enrollment of the 26 observational ones that give a count, is one of 10 that started in 2020, is one of 26 observational ones, reaches primary completion later than 30 of the 30 other live ones, and was the 21st registered.
229 studies on the registry are indexed under Tricuspid Valve Insufficiency; 111 are open to participants now.
Browse Tricuspid Valve Insufficiency studies →24 of the 51 studies in Tricuspid Valve Insufficiency with a site in Germany are open now. Recruiting first, the newest first:
Abbott Medical Devices · Sites in Germany, United States, France and 2 more countries
Ages 18+
LMU Klinikum · Sites in Germany
Ages 18+
Cardiovalve Ltd. · Sites in Germany
Ages 18–85
Heart and Diabetes Center North-Rhine Westfalia · Sites in Germany
Ages 18+
Robert Bosch Medical Center · Sites in Germany
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 81 Tricuspid Valve Insufficiency studies recruiting now, 67 (83%) set no upper age limit and none (0%) stop at 75 or younger; 7 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 120 Years · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 10 started in 2020.
This study's planned enrollment of 200 is below the median of 225 across 96 observational studies indexed under Tricuspid Valve Insufficiency.
Median enrollment 60 across the 25 interventional studies, 506 across the 26 observational. Of the 14 that completed or were terminated, 5 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 51 have an industry lead sponsor. The 10 most frequent:
Charite University, Berlin, Germany is the lead sponsor of 857 studies on the registry; 128 are open to participants now.
Charite University, Berlin, Germany has 4 studies filed under Tricuspid Valve Insufficiency — fewer than ten, so there is no comparison to draw.
6 of the studies in Tricuspid Valve Insufficiency with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05825898Ottawa Heart Institute Research CorporationOutcome of Patients With Severe Functional TR According to Medical, Transcatheter or Surgical Treatment | 2026-12 |
| NCT07464106Robert Bosch Medical CenterEvaluation of the Impact of Interventional Treatments for Symptomatic, Severe Tricuspid Valve Insufficiency on Renal Integrity and Function, as Well as on Physical Function and Activity in Older Adults. | 2026-12 |
| NCT06212193Innoventric LTDInnoventric Trillium™ Stent Graft Early Feasibility Study (EFS) | 2026-12-20 |
| NCT05797519VDyne, Inc.Clinical Safety and Efficacy of the VDyne Transcatheter Tricuspid Valve Replacement System for the Treatment of Tricuspid Regurgitation | 2026-12-30 |
| NCT07342036Hazem OmranProspective Study of Lead-associated Tricuspid Regurgitation in Patients Undergoing New Transvalvular Lead Insertion | 2027-01-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 51 studies in Tricuspid Valve Insufficiency with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The present study evaluates patients after interventional therapy of valvular diseases of the right heart. Follow-up examinations include medical history taking, laboratory measurements and an echo. The aim is to assess the different interventional therapies and their impact on patient's outcome.
The subject of the study is to register interventional therapies of right heart diseases (such as "cardioband" and "edge-to-edge" techniques of the tricuspid valve) performed in Berlin/ Brandenburg (primarily at the Charité, Universitätsmedizin Berlin). Based on the development and the increasing use of interventional therapies in tricuspid and pulmonary valve diseases, the impact on the patients' symptoms and life expectancy after interventions will be investigated. The aim is to identify patient subgroups that benefit the most.
Primary endpoints: Total mortality, cardiovascular mortality, heart failure hospitalization.
Secondary endpoints: NYHA class, NTproBNP, liver and kidney function (laboratory measurements), valve function, cardiac function, and cardiac morphology.
Patients after interventional therapy of valvular diseases of the right heart (such as "cardioband" and "edge-to-edge" techniques of the tricuspid valve) performed in Berlin/ Brandenburg (primarily at the Charité, Universitätsmedizin Berlin).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Catheter-based therapy of valve diseases of the right heart with various devices (e. g. TriClip, Cardioband).
Overall mortality
Number of deceased participants after 2 months after intervention
Time frame: 2 months after intervention
Cardiovascular mortality
Number of deceased participants after 2 months after intervention (cardiovascular cause of mortality)
Time frame: 2 months after intervention
Unscheduled hospitalization for heart failure progression
Number of participants with unscheduled hospitalization for heart failure progression after 2 months after intervention
Time frame: 2 months after intervention
NYHA class
New York Heart Association (NYHA) class (to rate dyspnea in heart failure patients)
Time frame: 2 months after intervention
NTproBNP
Laboratory measurement of NTproBNP 2 months after intervention
Time frame: 2 months after intervention
valve function
Echocardiographic quantification of valve function (proximal isovelocity surface area \[PISA\] method, effective regurgitant orifice \[ERO\], vena contracta \[VC\]) after 2 months after intervention
Time frame: 2 months after intervention
liver function
Laboratory measurement of bilirubin 2 months after intervention
Time frame: 2 months after intervention
kidney function
Laboratory measurement of creatinine 2 months after intervention
Time frame: 2 months after intervention
cardiac function
Echocardiographic measurement of cardiac function (left ventricular ejection fraction, tricuspid anular plane systolic excursion) after 2 months after intervention
Time frame: 2 months after intervention
cardiac morphology
Echocardiographic measurement of cardiac morphology (right ventricular and right atrial diameter) after 2 months after intervention
Time frame: 2 months after intervention
Plan to share: Yes — As part of the expected publications, it is planned to provide data of the study participants and more detailed information on inclusion and exclusion criteria (study protocol).
No publications or documents are linked to this record.
Started Jun 2020 (actual). Primary completion is estimated for Dec 2035, 186 months after the start.
Of 47 observational studies under Tricuspid Valve Insufficiency, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 106. This study's planned 186 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tricuspid Valve Insufficiency →
Charite University, Berlin, Germany →